Maftuchah Rochmanti is the Director of Education at Universitas Airlangga and serves as the First Chair of the Executive Board of the Indonesian Pharmacology Association (Pengurus Besar Ikatan Farmakologi Indonesia – PB IKAFARI). She completed her doctoral and master’s degrees at the Faculty of Medicine, Universitas Airlangga. In her academic role, she teaches pharmacology at the Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga. Her research focuses on pharmacology in non-communicable diseases, particularly diabetes mellitus and dyslipidemia, encompassing both conventional pharmacotherapy and the development and evaluation of herbal medicines. She is also an established author of pharmacology textbooks for medical and nursing education, contributing significantly to the dissemination and standardization of pharmacological knowledge across health professions.

Igor Rubinić, MD, is a clinical pharmacologist at the Clinical Hospital Centre Rijeka and a doctoral student in biomedical sciences at the Faculty of Medicine, University of Rijeka, Croatia. His research focuses on antimicrobial stewardship, multidrug-resistant organisms, and microbiome-based interventions, including faecal microbiota transplantation. He is a member of EurFMT and serves on the Executive Board of the European Drug Utilization Research Group (EuroDURG).

Neha Sharma is a PhD research scholar at Jamia Hamdard, New Delhi, India, working under the supervision of Prof. Divya Vohora in the Neurobehavioral Pharmacology Laboratory. Her research focuses on inflammation in knee joints and the role of cellular senescence and inflammation in osteoarthritis. She is currently investigating the therapeutic potential of senolytic agents in a preclinical mouse model of senescence-associated osteoarthritis. Her broader research interests lie in translational inflammation research. Prior to her PhD admission, she worked as an assistant professor for two years.

I hold a Master’s degree in Zoology and am currently pursuing my PhD at Banaras Hindu University (BHU). Research interests focus on immunological mechanisms underlying respiratory diseases, with particular emphasis on immune–metabolic reprogramming, oxidative stress, cellular stress responses, mitochondrial dysfunction, and mitochondria-endoplasmic reticulum crosstalk in airway inflammation. Current work investigates the pathophysiological processes contributing to the onset and progression of chronic respiratory disorders using integrative experimental approaches. Technical expertise includes laboratory mouse handling, mitochondrial isolation, PCR-based gene expression analysis, Western blotting, and immunofluorescence and confocal microscopy for the mechanistic investigation of respiratory pathophysiology.

Personal information Feifeng Song, Female Education PhD in Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Sep 2013–Jun 2018 Professional Experience Associate Chief Pharmacist, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Jan 2023–present Research Grants / Projects Principal investigator on >15 funded projects, including one National Natural Science Foundation of China (General Program), one NSFC Youth Program, one Zhejiang Provincial Natural Science Foundation Key Project, and multiple provincial and institutional grants. Publications Publications: >40 peer-reviewed papers, including 15 SCI-indexed articles as first or corresponding author in clinical pharmacy and pharmacology. 1.Song F, et al. Zebrafish patient-derived xenograft system for predicting carboplatin resistance and metastasis of ovarian cancer. Drug Resistance Updates. 2025, 78: 101162. 2.Song F, et al. Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis. Advanced Science (Weinh). 2024,11(24):e2306671. 3.Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy. Drug Resistance Updates. 2025, 83:101286.

Martina Šutovská, MD, PhD, is a Professor of Pharmacology at the Faculty of Medicine, Comenius University in Bratislava (Jessenius Faculty of Medicine in Martin), Slovakia, and Deputy Head of the Institute of Pharmacology. Her research focuses on experimental and clinical pharmacology, particularly respiratory pharmacology, cough mechanisms, and airway inflammation. She has authored or co-authored 68 peer-reviewed publications in impacted journals with over 950 citations, and is the author or co-author of three scientific monographs and four textbooks or educational texts.

Martina Šutovská, MD, PhD, is a Professor of Pharmacology at the Faculty of Medicine, Comenius University in Bratislava (Jessenius Faculty of Medicine in Martin), Slovakia, and Deputy Head of the Institute of Pharmacology. Her research focuses on experimental and clinical pharmacology, particularly respiratory pharmacology, cough mechanisms, and airway inflammation. She has authored or co-authored 68 peer-reviewed publications in impacted journals with over 950 citations, and is the author or co-author of three scientific monographs and four textbooks or educational texts.

Yasuhiro Takenouchi is a lecturer in the Department of Pharmacology at Kawasaki Medical School studying the role of lipid metabolism in pulmonary fibrosis. His research focuses on lipid phosphate phosphatase 3 (LPP3), a degrading enzyme of bioactive lipids such as S1P and LPA, and its contribution to fibrotic lung disease. Using mouse models and molecular approaches, he investigates how LPP3 expression is regulated in different lung cell populations.

Mika Tanaka is a registered dietitian and a master’s student at the Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Japan. Her research focuses on inflammation induced by outer membrane vesicles (OMVs) derived from Escherichia coli and the mechanisms by which red ginseng extracts suppress these inflammatory responses. She integrates perspectives from microbiology, immunology, and nutritional science in her research.

Mouhamadou Thiam is a pharmacist and former hospital intern. He holds a Master's degree in Drug Development, specializing in Pharmacology. Mouhamadou Thiam is in the third year of a PhD thesis in Pharmacology. He also holds a postgraduate diploma in Clinical Biology

Aifiona Yan Vestano graduated with a Bachelor of Science degree from the National University of Singapore. She is currently a Research Assistant in Yong Loo Lin School of Medicine Singapore under Dr Peh Hong Yong’s lab (HYPRI lab). Her research focuses on characterizing inflammation and its resolution within the maternal-fetal axis, with particular emphasis on pro-inflammation eicosanoids and specialised pro-resolving lipid mediators (SPMs). In 2025, she was awarded the Peter Wong Tsun-Hon Memorial Medal and Prize in Pharmacology for being the best performing Bachelor of Science (Life Sciences) student in pharmacology coursework and her final-year project.

Maggie Cunningham is Professor of Pharmacology at the University of Strathclyde, based in the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) in Glasgow, UK. Her research focuses on G-protein-coupled receptor (GPCR), gap junction and damage-associated molecular pattern (DAMP) regulation in cardiometabolic inflammation and cardiovascular complications associated with anti-cancer therapies. Alongside her research, Professor Cunningham is active in advancing pharmacology education and training, including the development of innovative and ethical experimental approaches aligned with the 3Rs (Replacement, Reduction and Refinement). She contributes to international pharmacology initiatives through roles with organisations including the British Pharmacological Society and the International Union of Basic and Clinical Pharmacology Education Section, where she serves as IUPHAR-Ed Secretary. Her work integrates mechanistic pharmacology research with research-led teaching and curriculum development to support the next generation of biomolecular scientists.

Lihui Wang is a Professor and PhD Supervisor at Shenyang Pharmaceutical University, serving as Dean of the Graduate School and Dean of the School of Clinical Pharmacy. His research focuses on tumor pharmacology, cancer epigenetics, drug resistance mechanisms, and molecular targeted therapies. He has led more than 20 national research projects, including two Major New Drug Development Programs and multiple National Natural Science Foundation grants. As corresponding author, he has published over 30 SCI papers in leading journals such as PNAS, Science Advances, EMBO Molecular Medicine, and Cancer Research, and has received national scientific awards. He has also delivered oral presentations at the World Congress of Basic Clinical Pharmacology (WCP), demonstrating strong experience in presenting research at major international scientific conferences.

Maggie Cunningham is Professor of Pharmacology at the University of Strathclyde, based in the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) in Glasgow, UK. Her research focuses on G-protein-coupled receptor (GPCR), gap junction and damage-associated molecular pattern (DAMP) regulation in cardiometabolic inflammation and cardiovascular complications associated with anti-cancer therapies. Alongside her research, Professor Cunningham is active in advancing pharmacology education and training, including the development of innovative and ethical experimental approaches aligned with the 3Rs (Replacement, Reduction and Refinement). She contributes to international pharmacology initiatives through roles with organisations including the British Pharmacological Society and the International Union of Basic and Clinical Pharmacology Education Section, where she serves as IUPHAR-Ed Secretary. Her work integrates mechanistic pharmacology research with research-led teaching and curriculum development to support the next generation of biomolecular scientists.

Prof Xiaoying Wang is a Professor at Tianjin University of Traditional Chinese Medicine, China, with expertise in Traditional Chinese Medicine and Pharmacology. Her research centers on the pharmacodynamic mechanisms of traditional Chinese medicines and new drug development, with a key focus on major chronic diseases including cardiovascular and respiratory disorders. She has presided over multiple national research projects, published numerous high-impact international papers, and currently serves as Vice Chairman of the Tianjin Pharmacological Society. She enjoys extensive academic influence in the field of translational pharmacology.

Ming Xiang, Ph.D., Professor at School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology. She presided over the National Natural Science Foundation projects and key science and technology projects in Hubei Province, and served as a council member of the Chinese Pharmacological Society, a member of the Chinese Society of Anti-inflammatory Immunology, and an executive director of the World Committee of TCM Immunology. Xiang’s research focuses on the mechanism of anti-tumor immunotherapy with new chemical and traditional Chinese medicine immunosuppressants, and covers related fields: investigating the pathogenesis of autoimmune diseases (T1D, RA, AIH, etc.) and chronic inflammation (pancreatitis, diabetic nephropathy, insulin resistance) based on innate-adaptive immunity crosstalk; studying immune cell functional reprogramming via epigenetics and cellular metabolism, as well as neuro-immuno-metabolic interactions in chronic metabolic diseases; exploring anti-tumor immunotherapy strategies and mechanisms; identifying biomarkers for anti-tumor drug resistance and immunosuppressant adverse reactions.

Professor Wen-Bin Wu is currently a Professor of Pharmacology at the School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. His research focuses on elucidating the pathophysiology of chronic rhinosinusitis (CRS) and on the development of natural products and synthetic compounds for the prevention and treatment of CRS. His laboratory primarily employs biochemical pharmacology, as well as molecular and cellular biology approaches, to investigate the underlying mechanisms of CRS.

I have worked about Neuropharmacology, inflammation, cancer, pharmacogenomics and mental health. I like so much to share Pharmacology Education since 2017. Also, I have work about in vivo, in vitro studies animals just as rats, mouse and horses in medical pharmacology laboratories since 2011. I am British Pharmacological Society(BPS) Ambassador since 2018 in Turkey and Middle East . I am innovator for new solutions with projects (more than 100 EU and UN funded projects)not only for Science but also humanity and animals and environment for better Planetary Health. I awarded BPS honorary award in 2024. My start-up(MD-MedinnovateDynamics) idea is base on mental health and Neuropharmacology and selected good start up Bio-innovation convention 2016, San Francisco, USA, and My project ’Saving Life Changing Lives’ selected as a winner of best project in Eurodesk over the European Union by European Parliament in 2018.

Dr. Shakta Mani Satyam, PhD, FAIMER Fellow, is an Associate Professor of Pharmacology at RAK College of Medical Sciences, RAK Medical and Health Sciences University, UAE, and serves as Director of the Translational Medical Research Centre and Central Animal Research Facility. He is also Chairman of the Institutional Animal Ethics Committee. With over 15 years of experience, Dr. Satyam is a leading translational pharmacologist specializing in preclinical human disease models, mechanistic pharmacology, cardiometabolic disorders, toxicology, drug repurposing, and nutraceutical interventions. He played a pivotal role in establishing the first MOCCAE-licensed central animal research facility in Ras Al Khaimah, developing comprehensive regulatory, ethical, and biosafety frameworks. Dr. Satyam has published over 76 peer-reviewed articles in high-impact Q1 journals and has secured more than AED 1 million in competitive research funding. His work bridges experimental pharmacology with clinical relevance, contributing to biomedical innovation and research capacity building in the UAE and internationally.

Born in Ethiopia, post primary education at General Wingate Comprehensive Secondary School, Addis Ababa, Ethiopia. There after winning a scholarship to former Czechoslovakia, interred Czech language centre as premedical preparatory school of Charles University and admitted to the former Faculty of Paediatrics, which later named 2nd Medical School of Charles University, where graduated /holding MD in 1992 . Then by interring postgraduate programme he defended, the thesis titled “Non-invasive Methods for Early Diagnosis of some Renal Diseases in Children” and awarded PhD degree in 1996. Then, trained as Paediatrician and later as Clinical Pharmacologist, holds Board Certificate from the Institute for Postgraduate Education in Medicine and is licenced by Czech medical chamber for both Paediatrics and Clinical Pharmacology practice including lectureship. His present position is at Clinical Pharmacology service affiliated to the Department of Medical Chemistry and Clinical Biochemistry, University Hospital in Motol, 2nd Medical School, Charles, University in Prague. The main interest and consultancy area being in particular therapeutic drug monitoring in needy patients including, paediatric and geriatric populations given their pharmacokinetic/pharmacodynamics differences and vulnerability. He is also dedicated to aid dosage adjustment for transplantation patients, oncology patients and others in intensive care including those with renal failure aiming therapy individualization for better overall outcomes and safety. As active in academia participates in pregraduate and postgraduate education both as a faculty member and as invited speaker in the field of clinical pharmacology. Dedicated to safe and better use of medicines for human wellbeing, as a recipient of the grant has successfully included clinical pharmacology education as optional subject in the curriculum for senior medical students at the 2nd Medical Faculty of Charles University teaching every summer term since 2011 to date. Among other scientific activities included bioequivalence studies as co-investigator and principal investigator as well as working on co- grant projects in the past. On long term, he has published more than 100 conference abstracts, including presentations as invited speaker and both oral and poster communications at domestic and international meetings. Tesfaye is also author and co-author of several original articles, case reports, conference proceedings, a monograph, few book-chapters and commentaries as letters to editors in the field of medicine.

I am a PhD candidate in the Graduate Institute of Biomedical Sciences at China Medical University. My research focuses on the mechanistic link between dyslipidemia and the progression of cardiovascular and cerebrovascular diseases. My previous publications have investigated the pathological roles of modified lipoproteins in vascular dysfunction and thrombosis. Currently, my work centers on ischemic stroke, particularly exploring lipid-mediated endothelial injury, blood–brain barrier disruption, and thrombolysis-associated complications, with the goal of translating molecular findings into clinically relevant therapeutic strategies.

Margarida Varela is a fourth-year PhD candidate at the University of Helsinki specialising in stem cell–based cardiac disease modelling. Her research centres on Hypoplastic Left Heart Syndrome (HLHS), a complex and multifactorial congenital heart defect for which no unifying pathogenic mechanism has yet been identified. Using cardiomyocytes differentiated from patient-derived pluripotent stem cells, she investigates molecular, transcriptomic, and functional differences between HLHS and healthy control cells to uncover cellular features that may drive disease development. Margarida has extensive expertise in human pluripotent stem cell technologies, cardiomyocyte differentiation, and cardiac biology, which she applies to discovery-driven studies of HLHS. She holds a Master’s degree in Genes, Drugs and Stem Cells – Novel Therapies from Imperial College London and a Bachelor’s degree in Molecular Biology from Middlesex University. Through her work, she aims to advance the biological understanding of HLHS and contribute to future progress in congenital heart disease research.

Masashi Wakabayashi is a second-year PhD student in the Department of Bio-informational Pharmacology, Graduate Program in Pharmacy, at the University of Shizuoka. His work focuses on sex differences in drug- induced QT prolongation. To minimize variability in genetic background, he generated human iPS cell (hiPSC) lines derived from a pair of dizygotic twins. Using cardiomyocytes differentiated from these hiPSCs, he investigates the effects of arrhythmogenic drugs and sex hormones. Through this research, he aims to establish a sex-aware cardiac safety evaluation system.

Xiaojing Wang is a PhD candidate at Adelaide University and conducts her research at the Basil Hetzel Institute. Her work investigates the mechanisms underlying impaired cardiac energy metabolism in diabetes, with a focus on mitochondrial function and substrate utilisation in heart failure. She has a particular interest in translational approaches that bridge experimental findings with potential therapeutic strategies to improve cardiac metabolic efficiency.

Dr. Wang received her Bachelor in Clinical Medicine (2002), Master in Pharmacology (2007) and Ph.D. in Pharmacology (2012) from Anhui Medical University, Hefei, China. She joined the Faculty of Anhui Medical University since July 2002 and completed her visiting scholar research at Department of Pharmacology, UCDavis. Her research interests focus on understanding the mechanisms of pathogenesis of inflammatory disease and inflammation-related cardiomyopathy, identifying novel targets for disease therapy and developing small-molecule compound with specific activity. She is now a professor of pharmacology and a principal investigator in Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education (Anhui Medical University).

Dr. Yan Wang is an Early Career Research Fellow in the Integrative Cardiovascular Pharmacology Group within the Department of Pharmacology at Monash University. She has more than 10 years’ experience in cardiovascular pharmacology, specialising in novel treatments for cardiovascular and renal diseases, particularly end-organ damage and fibrosis in the heart and kidney. Following completion of her Honours Degree with First Class Honours at Monash University, Yan worked as a Research Assistant before undertaking her PhD from 2016–2020. Her research has contributed to the development of novel peptides with high AT2R selectivity demonstrating significant anti-fibrotic and anti-inflammatory effects, resulting in a patent filing in 2018. During her postdoctoral training, Yan established high-throughput anti-fibrotic drug screening assays and a new myocardial infarction model in Australia. She has received numerous national and international awards recognising her research excellence and remains actively involved with HBPRCA and ASCEPT.

Prof Xiaoying Wang is a Professor at Tianjin University of Traditional Chinese Medicine, China, with expertise in Traditional Chinese Medicine and Pharmacology. Her research centers on the pharmacodynamic mechanisms of traditional Chinese medicines and new drug development, with a key focus on major chronic diseases including cardiovascular and respiratory disorders. She has presided over multiple national research projects, published numerous high-impact international papers, and currently serves as Vice Chairman of the Tianjin Pharmacological Society. She enjoys extensive academic influence in the field of translational pharmacology.

Wu Hongfei, PhD, Professor and doctoral supervisor at Anhui University of Chinese Medicine. I am an Outstanding Young Talent and Excellent Young Teacher of Anhui universities.I hold key academic roles in multiple national and provincial societies, and serve as a Young Editorial Board Member of Pharmcol Res: Mod Chin Med.My research concentrates on cardiovascular disease mechanisms and traditional Chinese medicine drug targets. I have published over 30 academic papers in Redox Biology, Phytomedicine and other journals. I have presided over 2 National Natural Science Foundation projects and more than 10 provincial projects. I have won several academic and teaching awards and own one authorized invention patent.

Dr. Yang Huihai received his PhD degree from the Faculty of Medicine at The Chinese University of Hong Kong, Hong Kong SAR of China, in 2023, and is currently an early-career researcher (postdoctoral fellow) at The Hong Kong Polytechnic University. His research centers on developing and applying novel therapeutic strategies for cardiovascular diseases by systematically investigating their pharmacological effects, molecular mechanisms, and drug delivery systems.

Atnaf Abate is a biomedical researcher with a strong interest in neuropharmacology and receptor signaling. Her current research investigates the functional effects of polyunsaturated fatty acids on cannabinoid receptors using cellular and molecular approaches.

Melitta is a second-year PhD candidate at Monash Institute of Pharmaceutical Sciences, working across the Analytical and Structural Neuropharmacology, and the Spatial Organisation of Signalling laboratories. Melitta’s current research investigates the M1 and M4 muscarinic acetylcholine receptors as targets for the treatment of schizophrenia, with a particular focus on biased agonism and signalling from compartmentalised intracellular locations.

Chrismawan Ardianto is an academic and researcher based in Surabaya, East Java, Indonesia, with over 10 years of experience in neuropharmacology. He holds a PhD from Hoshi University, Tokyo, and specializes in experimental brain circuitry and neuroinflammation. Ardianto has authored numerous peer-reviewed publications in neuropharmacology. His research has secured national grants from the Indonesian Ministry of Education, Culture, Research, and Technology since 2017. As an Associate Professor in the Department of Pharmacy Practice at Universitas Airlangga and a member of the Biomedical Pharmacy Research Group, he mentors emerging scholars and leads collaborative projects advancing therapeutic approaches for stroke recovery and neuropathic pain.

Dr. Urmila M. Aswar is Professor and Head of the Department of Pharmacology at Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune. With over 20 years of teaching and research experience, she has devoted her career to advancing pharmacological sciences, specializing in neuropharmacology, metabolic disorders, and herbal medicine. She holds an M.Pharm. and a Ph.D. in Pharmacology, with expertise in preclinical studies and drug evaluation, and has led numerous funded projects with multiple publications to her credit. Throughout her academic journey, Dr. Aswar has mentored numerous postgraduate and doctoral students, fostering research excellence and scientific inquiry. She has received multiple prestigious awards, including the Women Achiever Award from the Rotary Club of Pune in 2023, and has secured research grants from both national and international organisations. Her research focuses on integrating traditional medicinal knowledge with modern pharmacological approaches to discover novel treatments for neurological and metabolic disorders. Dr. Aswar actively contributes to the scientific community as a resource person, committee member, and reviewer for various journals and forums. Committed to education and innovation, she strives to bridge the gap between traditional medicine and contemporary drug discovery, mentoring the next generation of researchers and advancing healthcare through rigorous scientific exploration.

Niamh is a fourth year pharmacy student at Queen's University Belfast, Northern Ireland and emerging researcher specialising in neuropharmacology. Niamh graduated with a Bachelor of Science (Honours) from the University of Galway, Ireland in 2023. During this degree, she developed a thesis project evaluating the validity of a preclinical model of depression - research she has continued to extend and refine. This work was previously presented at the British Pharmacological Society conference in Manchester in 2023 and is being presented at the World Congress of Basic and Clinical Pharmacology 2026. In addition to her academic pursuits, she has gained valuable industry experience as a medical writing intern with UCB in Raleigh, North Carolina, where she prepared scientific and regulatory documents.

Cen Juan, whose doctor degree was obtained from China Pharmaceutical University, is a professor and doctoral supervisor at Henan University. Her research primarily focuses on the regulatory mechanisms of the microenvironment for major diseases and drug interventions. She has achieved systematic research results in the study of neurodegenerative diseases and multidrug resistance in tumors, and has developed a distinctive research direction in the development of natural drugs for treating cerebral ischemia. She has published over 60 SCI papers in journals such as ACS Central Science, Adv Healthc Mater, and Journal of Medicinal Chemistry, and holds 6 China national invention patents as the first inventor.

Yujing Weng is a graduate student at National Cheng Kung University, Taiwan. Her research focuses on the role of the gut microbiome in psychiatric disorders, particularly major depressive disorder. Her work aims to develop quantitative microbiome-based indicators and integrate them with clinical data to improve disease prediction and understanding of clinical outcomes.

Dr. Sayan Chatterjee, MBBS, MD (Pharmacology), is a Consultant Physician, Diabetologist, and Clinical Pharmacologist based in Howrah and Kolkata, India. A graduate of Midnapore Medical College and Hospital and postgraduate of the Institute of Post-Graduate Medical Education and Research (IPGMER), Kolkata, he combines a rigorous background in clinical medicine and pharmacological sciences with a passionate commitment to evidence-based diabetes care and metabolic research. Dr. Chatterjee’s academic interests lie at the crossroads of pharmacotherapeutics, precision medicine, and metabolic regulation, particularly focusing on immunometabolic mechanisms in type 2 diabetes, digital health applications in insulin safety, and the role of pharmacogenomics in personalized treatment. His ongoing projects include a systematic review of GLP-1 analogues for weight modulation, a meta-analysis on immunometabolic interplay in diabetes, and translational research on rituximab therapy in central nervous system demyelinating disorders. Beyond his research, Dr. Chatterjee is an active patient educator and author, dedicated to translating complex clinical science into accessible knowledge for patients. He is the author of several forthcoming patient-oriented books, including Decoding Diabetes, Living Well with Insulin, and Gut Feeling: Understanding Digestive Health from the Inside Out, each designed to empower individuals with chronic diseases through clear, culturally contextualized medical literacy. Dr. Chatterjee also leads digital health initiatives through his proprietary mobile and web platform “Dr. Sayan Chatterjee,” which integrates teleconsultation, glucose monitoring guidance, and educational content. His clinical practice emphasizes safe insulin initiation, home-based dose titration, and rational use of pharmacological therapy tailored to Indian populations. He is currently pursuing academic collaboration with major teaching hospitals, contributing to research mentorship, pharmacology teaching, and continuing medical education programs.

Vichuda Charoensaensuk is a neuroscientist with demonstrated expertise in animal behavioral paradigms, cellular and molecular neurobiology, and pharmacological research targeting neurological disorders. Her current work focuses on elucidating the mechanisms and therapeutic efficacy of pharmacological agents in preclinical models of stress-related behavioral impairments.

As a Ph.D. student, I have been conducting doctoral research in my laboratory since 2021 and has demonstrated exceptionally experimental methodology and admirable investigation in neuroscience during this period. I am passionate about scientific research and have shown remarkable professionalism in completing various animal behavior experiments. I have also displayed notable leadership and management skills as an excellent communicator. To designing and executing complex experimental protocols, I spend more time validating the experiments, analyzing data and interpreting results, contributed significantly to neuroscience. In my previous study, I investigated the mice subjected to social defeat stress, a well-established rodent model of anxiety disorder and PTSD, in the presence of aggressor mice exhibited social avoidance and anxiety-like behaviors. I validated that melatonin receptor activation by melatonin and ramelteon regulates social stress-induced behavioral abnormalities. In the present study, I keep studying the potential mechanisms of PPAR alpha on affective disorders.

Dr. Kai-Yun Chen is a Professor in the Ph.D. Program in Medical Neuroscience at Taipei Medical University. She received her Ph.D. in Life Sciences and M.S. in Microbiology and Immunology from the National Defense Medical Center, Taiwan, and completed postdoctoral training at the National Health Research Institutes and Taipei Medical University. Professor Chen’s research focuses on translational medicine in traumatic brain injury, neurodegenerative disease models, and stem cell–based regenerative medicine. Her work explores molecular mechanisms underlying neuroprotection, neuroinflammation, and brain repair, with particular emphasis on mesenchymal stem cell–based therapies and immunomodulatory strategies for stroke and brain injury. By integrating preclinical models with clinical perspectives, she aims to develop innovative and clinically applicable therapeutic approaches for neurological disorders. She has published extensively in leading international journals and has received multiple honors, including the Outstanding Teacher Award at Taipei Medical University.

Ayano Chiba, PhD, is a lecturer in the Department of Pharmacology at Yamagata University School of Medicine, Japan. She earned her PhD in Medical Science from Osaka University in 2017. To pursue her interest in signal transduction, she studied the visualization of signal transduction using fluorescent protein reporters at the National Cerebral and Cardiovascular Center in Japan. She is currently working to elucidate the function of midnolin, a genetic risk factor for Parkinson's disease.

Charmaine is a first-year PhD student in the Department of Pharmacology at Monash University. Her research focuses on exploring therapy-induced cellular senescence (TIS) in medulloblastoma and evaluating senotherapeutic strategies to selectively target senescent tumour cells in various models. She aims to determine whether TIS represents a therapeutic vulnerability that can be exploited to enhance the efficacy of current treatment regimens. Her work seeks to better understand how treatment-associated senescence may contribute to tumour growth and aggressive recurrence, and whether targeting these senescent populations following exposure to standard-of-care cancer treatments could improve outcomes in paediatric brain cancer.

Ye Eun Cho is a researcher at Kangwon National University, Chuncheon, Republic of Korea. She received her academic training in life sciences with a focus on neuropharmacology and behavioral neuroscience. Her research investigates the antipsychotic-like effects of natural compounds, particularly Dracocephalum moldavica and its major compound, tilianin, using schizophrenia mouse models. Her recent work focuses on PDE10A as a non-dopaminergic therapeutic target and its downstream cAMP/PKA/CREB signaling pathway, integrating behavioral assays, molecular docking, enzyme inhibition assays, and biochemical analyses. Through this approach, she aims to elucidate mechanistically grounded strategies for improving cognitive and behavioral deficits associated with schizophrenia.

Sylvain Couderc, PharmD, master2 research Pharmacoepidemiology and Pharmacovigilance, hospital practitioner (medical biologist) at the Pharmacology-Toxicology and Pharmacovigilance Laboratory (Limoges University Hospital Center, France), member of the SFPT (French Society of Pharmacology and Therapeutics), member of the STP group and the STP subgroup for psychotropic drugs, member of 1248 INSERM unit (Pharmacology & Transplantation)

Sylvain Couderc, PharmD, master2 research Pharmacoepidemiology and Pharmacovigilance, hospital practitioner (medical biologist) at the Pharmacology-Toxicology and Pharmacovigilance Laboratory (Limoges University Hospital Center, France), member of the SFPT (French Society of Pharmacology and Therapeutics), member of the STP group and the STP subgroup for psychotropic drugs, member of 1248 INSERM unit (Pharmacology & Transplantation)

Dr. Saibal Das is a Clinical Pharmacologist and Scientist E (Medical) at the Indian Council of Medical Research – National Institute for Research in Bacterial Infections, Kolkata, India. He is also an Affiliated Researcher at Karolinska Institutet and serves as an Assistant Professor at the Academy of Scientific and Innovative Research, India, with extensive teaching and mentoring experience. His work focuses on translating research into policy, guidelines, and improved healthcare outcomes. He holds a PhD (Medical Science), DM (Clinical Pharmacology), MD (Pharmacology), and MBBS. Dr. Das has expertise in clinical trials, pharmacoepidemiology, medication safety, and evidence synthesis, with over 15 years of research experience across clinical, academic, and regulatory settings. He has served as Principal Investigator on multiple government-funded projects, including ICMR-INTENT and the Technical Resource Centre. Dr. Das has authored more than 120 peer-reviewed publications with significant citation impact (h-index 25). He is an active member of national and international scientific committees, regulatory bodies, and ethics boards, and has received numerous national and international awards, fellowships, and travel grants.

Alexia Defrancesco is an MRes student at the University of Technology Sydney. Their research focuses on how environmental exposures, such as air pollution, influence cognitive function and long-term neurological outcomes.

Dr Natalie Diepenhorst is a translational drug discovery leader focused on accelerating the development of new therapeutics for central nervous system disorders. She leads the Molecular and Translational Drug Discovery (MTDD) Laboratory at the Monash Institute of Pharmaceutical Sciences, where her work integrates pharmacology, structural biology, and translational science to deliver patient-informed, commercially aligned research. Her research operates at the interface of academia and the pharmaceutical industry, with a strong emphasis on advancing high-value, challenging targets toward clinical development through rigorous science and strategic collaboration.

Dr. Ryota Eguchi is an Assistant Professor at Hokkaido University. He received his Ph.D. in Veterinary Medicine from Hokkaido University. His research focuses on neuropharmacology and glial biology, particularly the role of purinergic signaling, astrocyte morphology, and stress-related neuropsychiatric disorders.

Barbara Fülöp began her research career in 2017 as an undergraduate student at the Department of Pharmacology and Pharmacotherapy, Medical University of Pécs, Hungary. She later obtained her medical degree and pursued Ph.D. studies focusing on neuroinflammatory mechanisms underlying chronic pain conditions, successfully defending her thesis in 2025. Her research expertise includes animal behavioral testing, pain assessment, and immunohistochemical analysis, with a particular interest in neuroinflammatory signaling. She is committed to contributing to more precise and effective treatments for chronic, difficult-to-treat pain disorders.

Heon Yung Gee, MD, PhD, is an Associate Professor in the Department of Pharmacology at Yonsei University College of Medicine in Seoul, Korea. He received his BS and MS degrees from Korea Advanced Institute of Science and Technology, followed by an MD and PhD from Yonsei University. After postdoctoral training at the University of Michigan and faculty appointments at Boston Children’s Hospital and Harvard Medical School, he joined Yonsei University, where he leads research at the intersection of human genetics, disease mechanisms, and therapeutics development. His work has contributed to the understanding of hearing loss, inherited kidney diseases, cilia-related disorders, and translational therapeutic strategies, including gene and RNA-based therapies, with publications in leading journals.

Dr. Gottlieb obtained his Ph.D. in Pharmacology at Louisiana State University Health Sciences Center-New Orleans in 2004 and pursued his postdoctoral research at University of Texas Health-San Antonio in the Department of Pharmacology studying the role opioid systems play in the regulation of renal and cardiovascular function. Dr. Gottlieb’s research is currently funded by the NIH, 5R16GM145433. In addition to his research, Dr. Gottlieb is primarily involved in teaching Pharmacology to Pharmacy, Optometry, and Physical Therapy students at the University of the Incarnate Word and University of Texas Health, both in San Antonio, Texas. Dr. Gottlieb is a member of a number of professional societies which include the American Society for Pharmacology and Experimental Therapeutics (ASPET), the American Physiological Society (APS), and American Association of Colleges of Pharmacy (AACP). Within those societies, he has served in several executive committees and as Chair of the Division of Pharmacology Education Committee.

Mukaddes Gmüştekin was born in 1970 in Izmir, Turkey. She graduated from Ege University Faculty of Medicine in 1993. From 1995 to 1999, she completed her residency in Izmir at Dokuz Eylul University, Faculty of Medicine, Department of Medical Pharmacology. Dr. Gümüştekin also received her doctoral degree in Basic Oncology from the Dokuz Eylul University, Institute of Health Sciences, in 2008. Since then, she has continued her academic career at the same university. She visited Hematology Laboratory of Karolinska Institute in 2001. Between 2017-2018, she visited Wolfson Center of Personalized Medicine, Liverpool University and participated research on UPGx Horizon 2020 study, with a TUBITAK-2219 scholarship. She has supervised several residency students, master’s and PhD students at the university, as well as published scientific research articles, case reports, and reviews in scientific journals including Web of Science Core Collection indexes. Her research focuses on personalised medicine in order to optimise drug efficacy and minimise toxicity and also, experimetal diabetes models, radiation and contrast media-induced damages, small GTPases and cancer. She has served on the editorial board of BMC Pharmacology and Toxicology since 2017. She contributed to the European Diploma in Radiology (EDIR) as a member of the Written Review Committee from 2018 to 2024. Mukaddes Gümüştekin had served as the Head of the Department of Medical Pharmacology and the Head of the Department of Clinical Pharmacology at Dokuz Eylül University.

Meei-Ling Sheu is a Lifetime Distinguished Professor and Director of the Institute of Biomedical Sciences, College of Life Sciences, National Chung Hsing University, Taichung, Taiwan. In recent years, she has also focused on innovation, research and development, and management in the biotechnology industry, serving as a unit director. With over 20 years of experience in basic and translational research on tumor metastasis and vascular medicine, Professor Sheu has published more than 100 peer-reviewed articles and led several national-level research grants. Her current work centers on integrating advanced small-molecule development and imaging diagnostics into potential therapeutic pathways. Her research aligns closely with the theme of the 20th World Congress of Basic and Clinical Pharmacology (WCP 2026) — “Advancing Pharmacology Globally Through Collaboration and Discovery.” She will address the interface between specific molecular targets and tumor-associated macrophages in cancer metastasis. Outside of her professional role, Professor Sheu enjoys mountain climbing and swimming. For more information, please visit https://biomed.nchu.edu.tw/node/352.

Davor Štimac, MD PhD is a graduate of the School of Medicine, University of Rijeka, Croatia. He is the Head of the Specialty Hospital Medico and full professor at School of Medicine, University Rijeka, Croatia. He is the former President of the Croatian Society of Gastroenterology, Croatian Pancreatic Club, vice president of Croatian Academy of Medical Sciences. He is a President of Croatian Society for Obesity. He is a member of the European Board of Gastroenterology, a member of the WGO Guidelines committee, a member of UEG General Assembly and a member of European Association for Gastroenterology,Endoscopy and Nutrition Council. His main scientific interests are focused on hepatic and pancreatic diseases and obesity. He has published more than 400 abstracts and articles in peer-reviewed journals.

I am a master student at Proteomics Core Lab in China Medical University, Taiwan, specializing in the biochemical mechanisms. My work bridges experimental pharmacology, specifically TCM-based enzyme inhibition with advanced analytical workflows. My research integrates wet-lab modeling, including animal model with computational tools like molecular docking and MD simulations to advance our understanding of the inhibition efficiency.

Dr. Chun Wang, M.D., Ph.D., is an Associate Professor at the Institute of Clinical Pharmacology, Anhui Medical University. His research focuses on anti-inflammatory immunopharmacology, specifically in the discovery of new drug targets for chronic kidney diseases, structural modification of natural bioactive small molecules, and translational research. He has contributed to the structural modification of active components from Paeonia lactiflora and Moutan Cortex (authentic Anhui medicinal herbs), resulting in the three Chinese invention patents. Dr. Wang has led multiple grants, including projects funded by NSFC and the Key Research and Development Program of Anhui Province. His work has been published in peer-reviewed journals such as the British Journal of Pharmacology and Acta Pharmacologica Sinica. Dr. Wang serves the academic community as a Youth Committee Member of the Anti-Inflammatory Immunopharmacology Professional Committee, Chinese Pharmacological Society, and as a Committee Member of the Immunology Branch, China Association of Chinese Medicine.

Dong Wang is Director of Pharmacy, Master Supervisor and MTM Pharmacist at Tianjin Cancer Hospital Airport Hospital. He holds key academic positions in national and provincial professional committees, including the Chinese Anti-Cancer Association and Tianjin Pharmacological Society. He obtained his Ph.D. in Traditional Chinese Medicine and focuses on oncology pharmacy research. He has led multiple funded projects, published numerous academic papers, and specializes in preclinical drug synergy mechanisms and real-world clinical evaluation of anticancer agents.

Xingxin Wu, PhD, is Professor of Pharmacology at the School of Life Sciences, Nanjing University, and Principal Investigator at the State Key Laboratory of Pharmaceutical Biotechnology. His research focuses on immunopathology and pharmacological strategies for liver fibrosis, including activation of endogenous anti-fibrotic signalling to restore hepatic stellate cell homeostasis. He has published in Nature Communications, PNAS, Nucleic Acids Research, and APSB, and has received multiple national and provincial awards.

Hongkang Wu completed a Bachelor of Biomedicine (Degree with Honours) at the University of Melbourne in 2021, conducting his Honours research at The Florey. He continued his graduate studies within the same group under the supervision of Professor Akhter Hossain, Professor Ross Bathgate, Professor John Furness, and Dr Ruslan Pustovit. His doctoral research focuses on developing next-generation therapeutics based on the insulin/relaxin superfamily of peptides, with particular emphasis on simplified insulin-like peptide 5 (INSL5) analogues as colon motility regulators. By integrating solid-phase peptide synthesis, medicinal chemistry, receptor pharmacology, and structure–activity relationship studies, he designs drug-like analogues with enhanced potency and selectivity to modulate relaxin family peptide receptors (RXFPs). Hongkang has published first-author papers in high-impact journals such as the Journal of Medicinal Chemistry. He is passionate about bridging the gap between discovery and application in peptide science and welcomes interdisciplinary collaborations in peptide drug design, GPCR biology, and therapeutic innovation.

Dr. Li Zuo is a Professor and Doctoral Supervisor at Anhui Medical University. She serves as the Deputy Director of the Department of Science and Technology Industry and the Director of the Innovation Experimental Teaching Center for College Students. Dr. Zuo received her Ph.D. from Anhui Medical University in 2014. She subsequently completed a five-year postdoctoral fellowship (2017-2022) at Harvard Medical School under the mentorship of Prof. Jerrold R. Turner, a leading expert in intestinal barrier function. Her research is dedicated to inflammatory bowel disease (IBD), the gut-liver axis, and tumor immunotherapy-induced colitis. Dr. Zuo has received numerous grants from the National and Provincial Natural Science Foundations of China. She is a recipient of the Distinguished Young Scholar award of Anhui Province. To date, Dr. Zuo has published more than 20 papers in highly prestigious journals including Gastroenterology, Gut, Journal of Clinical Investigation, and Cellular and Molecular Gastroenterology and Hepatology.

An Zhu, Associate Professor, Master Tutor. Received bachelor's and master's degrees in medicine from Lanzhou University from 2009 to 2017, and received doctor's degree in medicine from Peking University in 2020. It mainly studies pharmacology, toxicology and RNA modification. He is the member of Traditional Chinese Medicine Toxicology and Safety Research Branch of Chinese Medicine Association, Supervisor of Engineering Society of biology, Fujian Province, Class C high-level talents in Fujian Province. Member of Chinese Society of Toxicology, Chinese Society of Traditional Chinese Medicine and Chinese Society of Environmental Mutagens.

Peichun Ye. A graduate student at Fujian Medical University since 2025.Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou 350108, China.

I am a researcher at West China Hospital, Sichuan University, focusing on tumor-targeted therapy and metabolic reprogramming. My research involves identifying targetable vulnerabilities in malignant tumors, with findings published in journals such as Signal Transduct Target Ther, Nature Communications, Journal of Cell Biology, European Journal of Medicinal Chemistry, Cancer & Metastasis Reviews, and MedComm Oncology.

Chloe J. Peach is an Assistant Professor in Molecular Pharmacology. She completed an undergraduate degree in Neuroscience at the University of Nottingham, before doing a Ph.D. funded by the BPS AJ Clark Scholarship exploring how growth factors interact with receptor tyrosine kinases (RTK) in tumour angiogenesis. Chloe then moved to the U.S. as a postdoctoral fellow at New York University, studying both G protein-coupled receptors (GPCRs) and RTKs involved in chronic pain funded by the Leon Levy Fellowship in Neuroscience. In 2023, she returned to the University of Nottingham to establish her own research group, receiving funding from the Academy of Medical Sciences and Royal Society. Chloe has won multiple awards, including the University-wide Ian Tomlin Prize and U.K.-wide BPS Vogt Prize. Based within the Centre of Membrane Proteins and Receptors (COMPARE), Dr. Peach leads a team interested in how receptor tyrosine kinases are modulated by their local microenvironment.

Jiuyang Zhang is a postgraduate student majoring in Chinese Materia Medica at Anhui University of Chinese Medicine. His research focuses on neurodegenerative diseases, particularly the pharmacological effects of traditional Chinese medicine on vascular dementia, involving neuroprotection, synaptic remodeling and related signaling pathways. He is proficient in cell culture, animal models and molecular biology techniques with a rigorous academic attitude. He has been awarded the First-Class Scholarship for his outstanding academic performance. He is dedicated to exploring the modern mechanisms of traditional Chinese medicine and its application in treating nervous system diseases.

Wang Ning Male, PhD in Chinese Materia Medica, Postdoctoral Fellow in Pharmacy, Professor and Doctoral Supervisor. Director of the Department of Chinese Materia Medica Pharmacology, Anhui University of Chinese Medicine; Director of the Institute of Efficacy and Safety Evaluation of Chinese Materia Medica, Anhui Academy of Chinese Medicine. Senior Visiting Scholar at Western Sydney University, Australia. Leader of the Key Discipline of Chinese Materia Medica Pharmacology in Anhui Province. He has presided over the National Natural Science Foundation of China and other provincial and ministerial projects. He has received provincial teaching achievement awards and excellent paper awards at national pharmacy postdoctoral forums. He has published over 10 papers in international journals. His research focuses on cerebrovascular pharmacology of traditional Chinese medicine and neuroprotective mechanisms of Chinese medicinal compounds.

Beata Sperlagh is the Director, Research professor and Head of Laboratory of Molecular Pharmacology of HUN-REN Institute of Experimental Medicine, Budapest, Hungary; the member of the Academia Europaea and the ordinary member of the Hungarian Academy of Sciences. She graduated as an MD at the Semmelweis University, Budapest, in 1987, obtained her PhD in 1994 and board certificate in clinical pharmacology in 2000. Her major scientific interest is neuropharmacology. She is a leading expert in the field of purinergic signalling in the nervous system. Her recent major achievements are the discovery of the P2X7 purinergic receptors regulating neurotransmission and validation of P2X7 receptor as a new drug target in psychiatric disorders. She has established relationship with pharmaceutical companies. Dr. Sperlágh is the former President of the Hungarian Society for Experimental and Clinical Pharmacology; the current Governing Chair and member of the Executive Committee of IUPHAR. .

Liu Defeng, a Senior Nurse in the Department of Neurology at the 958th Army Hospital, Jiangbei Campus of Southwest Hospital, serves as the Chief Nursing Officer and Head of Departmental Teaching. With extensive experience in clinical nursing and teaching, she demonstrates exceptional dedication and solid professional competence, significantly contributing to the improvement of nursing quality and talent development within her department.